BECTON DICKINSON & CO

BDX 10-K · FY 2025
API behind this page

BDX FY 2025 request

Playground key active
Request URL /api/financials?ticker=BDX&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 21,840 20,178 +8.2%
Show Business Segments breakouts
Interventional · Non Us 929 904 +2.8%
Interventional · Non Us 397 363 +9.4%
Interventional · Non Us 345 319 +8.2%
Interventional · Non Us 1,671 1,586 +5.4%
Interventional · Operating Segments 5,217 4,980 +4.8%
Interventional · Peripheral Intervention 1,996 1,933 +3.3%
Interventional · Surgery 1,572 1,492 +5.4%
Interventional · Urology and Critical Care 1,649 1,554 +6.1%
Interventional · US 1,067 1,029 +3.7%
Interventional · US 1,175 1,130 +4.0%
Interventional · US 1,303 1,236 +5.4%
Interventional · US 3,545 3,394 +4.4%
Life Sciences · Biosciences 1,458 1,512 -3.6%
Life Sciences · Diagnostic Solutions 1,838 1,846 -0.4%
Life Sciences · Non Us 865 935 -7.5%
Life Sciences · Non Us 1,083 1,064 +1.8%
Life Sciences · Non Us 890 882 +0.9%
Life Sciences · Non Us 2,838 2,881 -1.5%
Life Sciences · Operating Segments 5,167 5,191 -0.5%
Life Sciences · Specimen Management 1,871 1,833 +2.1%
Life Sciences · US 593 577 +2.8%
Life Sciences · US 755 782 -3.5%
Life Sciences · US 981 952 +3.0%
Life Sciences · US 2,328 2,310 +0.8%
Medical · Advanced Patient Monitoring 1,082 74 +1362.2%
Medical · Medication Delivery Solutions 4,575 4,429 +3.3%
Medical · Medication Management Solutions 3,474 3,297 +5.4%
Medical · Non Us 424 27 +1470.4%
Medical · Non Us 1,787 1,768 +1.1%
Medical · Non Us 664 670 -0.9%
Medical · Non Us 1,666 1,644 +1.3%
Medical · Non Us 4,540 4,110 +10.5%
Medical · Operating Segments 11,456 10,074 +13.7%
Medical · Pharmaceutical Systems 2,324 2,273 +2.2%
Medical · US 658 47 +1300.0%
Medical · US 2,789 2,661 +4.8%
Medical · US 2,810 2,627 +7.0%
Medical · US 659 629 +4.8%
Medical · US 6,916 5,964 +16.0%
Show Geography breakouts
Asia 3,093 2,906 +6.4%
EMEA 4,729 4,402 +7.4%
Non Us 9,049 8,515 +6.3%
Other 1,227 1,207 +1.7%
US 12,790 11,663 +9.7%
Show Consolidation Items breakouts
Operating Segments 21,840 20,245 +7.9%
Cost of Revenue 11,915 11,053 +7.8%
Show Business Segments breakouts
Interventional · Operating Segments 1,712 1,693 +1.1%
Life Sciences · Operating Segments 2,490 2,538 -1.9%
Medical · Operating Segments 5,464 5,015 +9.0%
Show Consolidation Items breakouts
Operating Segments 9,666 9,245 +4.6%
Selling, General & Administrative 5,278 4,857 +8.7%
Show Product Lines breakouts
Shipping And Handling 736 702 +4.8%
Show Business Segments breakouts
Interventional · Operating Segments 997 945 +5.5%
Life Sciences · Operating Segments 721 702 +2.7%
Medical · Operating Segments 1,312 1,031 +27.3%
Show Consolidation Items breakouts
Operating Segments 3,030 2,679 +13.1%
Research & Development 1,265 1,190 +6.3%
Show Business Segments breakouts
Interventional · Operating Segments 255 226 +12.8%
Life Sciences · Operating Segments 315 336 -6.2%
Medical · Operating Segments 523 447 +17.0%
Show Consolidation Items breakouts
Operating Segments 1,092 1,009 +8.2%
Integration Restructuring And Transaction Expense 408 458 -10.9%
Show Consolidation Items breakouts
Material Reconciling Items 408 458 -10.9%
Other Operating Income Expense Net 396 222 +78.4%
Show Business Segments breakouts
Medical · Operating Segments -17 2 -950.0%
Show Consolidation Items breakouts
Operating Segments -17 2 -950.0%
Total Costs & Expenses 19,261 17,780 +8.3%
Operating Income 2,579 2,397 +7.6%
Show Business Segments breakouts
Interventional · Operating Segments 2,253 2,115 +6.5%
Life Sciences · Operating Segments 1,641 1,616 +1.5%
Medical · Operating Segments 4,140 3,583 +15.5%
Show Consolidation Items breakouts
Operating Segments 8,034 7,314 +9.8%
Interest Expense -613 -528 -16.1%
Interest Income 38 163 -76.7%
Other Non-Operating Income (Expense) -123 -28 -339.3%
Income Before Taxes 1,881 2,005 -6.2%
Income Tax Expense (Benefit) 203 300 -32.3%
Income Loss From Continuing Operations 1,678 1,705 -1.6%
Net Income 1,678 1,705 -1.6%
Show Equity Components breakouts
Retained Earnings 1,678 1,705 -1.6%
Net Income Loss Available To Common Stockholders Basic 1,678 1,705 -1.6%
Income Loss From Continuing Operations Per Basic Share 5.83 5.88 -0.9%
EPS (Basic) 5.83 5.88 -0.9%
Income Loss From Continuing Operations Per Diluted Share 5.82 5.86 -0.7%
EPS (Diluted) 5.82 5.86 -0.7%
Operating Expenses (FY) — — —
Show Consolidation Items breakouts
Corporate Non Segment -2,628 -2,529 -3.9%
Comprehensive Income 1,515 1,521 -0.4%
Wtd Avg Shares (Basic) 287,648 289,763 -0.7%
Wtd Avg Shares (Diluted) 288,509 291,009 -0.9%
Interest Income Expense Net (FY) — — —
Show Consolidation Items breakouts
Material Reconciling Items -575 -364 -58.0%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 641 1,717 -62.7%
Restricted Cash And Investments Current 210 139 +51.1%
Other Short Term Investments 8 445 -98.2%
Accounts Receivable 2,994 3,033 -1.3%
Inventory 3,894 3,843 +1.3%
Other Assets Current 1,508 1,292 +16.7%
Total Current Assets 9,255 10,468 -11.6%
Non-Current Assets
Property, Plant & Equipment 6,997 6,821 +2.6%
Goodwill 26,612 26,465 +0.6%
Show Business Segments breakouts
Interventional 12,764 12,729 +0.3%
Life Sciences 914 904 +1.1%
Medical 12,934 12,832 +0.8%
Other Non-Current Assets 3,056 2,615 +16.9%
Total Assets 55,325 57,286 -3.4%
Operating Lease Right-of-Use Assets 885 876 +1.0%
Intangible Assets 9,389 10,871 -13.6%
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 2,231 2,635 -15.3%
Developed Technology Rights 6,651 7,733 -14.0%
Intellectual Property 507 503 +0.8%
Other Assets
Core And Developed Technology Net 6,651 7,733 -14.0%
Finite Lived Customer Relationships Net 2,231 2,635 -15.3%
Other Intangible Assets Net 523 549 -4.7%
Current Liabilities
Debt Current 1,560 2,170 -28.1%
Accounts Payable 1,974 1,896 +4.1%
Accrued Liabilities 3,103 3,476 -10.7%
Employee Related Liabilities Current 1,346 1,246 +8.0%
Accrued Income Taxes Current 329 168 +95.8%
Total Current Liabilities 8,313 8,956 -7.2%
Current Portion of Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
1.208% Notes due June 4, 2026 704 — —
Non-Current Liabilities
Long-Term Debt 17,621 17,940 -1.8%
Show Debt Instrument breakouts
0.334% Notes due August 13, 2028 1,054 1,004 +5.0%
1.213% Notes due February 12, 2036 701 668 +4.9%
1.336% Notes due August 13, 2041 1,049 999 +5.0%
1.900% Notes due December 15, 2026 586 559 +4.8%
1.957% Notes due February 11, 2031 995 994 +0.1%
2.823% Notes due May 20, 2030 747 746 +0.1%
3.519% Notes due February 8, 2031 876 835 +4.9%
3.553% Notes due September 13, 2029 936 891 +5.1%
3.700% Notes due June 6, 2027 1,722 1,721 +0.1%
3.794% Notes due May 20, 2050 554 554 0.0%
3.828% Notes due June 7, 2032 1,168 1,113 +4.9%
4.029% Notes due June 7, 2036 933 889 +4.9%
4.298% Notes due August 22, 2032 496 496 0.0%
4.669% Notes due June 6, 2047 1,462 1,460 +0.1%
4.685% Notes due December 15, 2044 938 934 +0.4%
4.693% Notes due February 13, 2028 798 797 +0.1%
4.874% Notes due February 8, 2029 622 622 0.0%
4.875% Notes due May 15, 2044 244 244 0.0%
5.000% Notes due November 12, 2040 90 90 0.0%
5.081% Notes due June 7, 2029 597 596 +0.2%
5.110% Notes due February 8, 2034 546 545 +0.2%
6.000% Notes due May 15, 2039 121 121 0.0%
6.700% Debentures due August 1, 2028 114 115 -0.9%
6.700% Notes due December 1, 2026 154 158 -2.5%
7.000% Debentures due August 1, 2027 117 118 -0.8%
Other long-term debt 1 1 0.0%
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent 1,069 942 +13.5%
Show Retirement Plan Type breakouts
Pension Plans Defined Benefit 482 443 +8.8%
Other Non-Current Liabilities 2,933 3,558 -17.6%
Operating Lease Liabilities 704 667 +5.5%
Stockholders' Equity
Common Stock 371 371 0.0%
Additional Paid In Capital Common Stock 20,075 19,893 +0.9%
Retained Earnings 16,622 16,139 +3.0%
Common Stock Shares Held In Employee Trust1 25 25 0.0%
Treasury Stock Value -9,808 -8,807 -11.4%
Accumulated Other Comprehensive Income -1,895 -1,732 -9.4%
Total Stockholders' Equity 25,390 25,890 -1.9%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -636 -557 -14.2%
Accumulated Gain Loss Net Cash Flow Hedge Parent 94 70 +34.3%
Accumulated Other Comprehensive Income -1,895 -1,732 -9.4%
Accumulated Translation Adjustment -1,353 -1,244 -8.8%
Additional Paid In Capital 20,075 19,893 +0.9%
Common Stock 371 371 0.0%
Deferred Compensation Share Based Payments 25 25 0.0%
Retained Earnings 16,622 16,139 +3.0%
Treasury Stock Common -9,808 -8,807 -11.4%
Total Liabilities & Equity 55,325 57,286 -3.4%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation & Amortization 2,462 2,286 +7.7%
Show Business Segments breakouts
Interventional · Operating Segments 795 786 +1.1%
Life Sciences · Operating Segments 261 272 -4.0%
Medical · Operating Segments 1,393 1,216 +14.6%
Show Consolidation Items breakouts
Corporate Non Segment 14 13 +7.7%
Stock-Based Compensation 258 247 +4.5%
Deferred Income Taxes And Tax Credits -474 -211 -124.6%
Increase Decrease In Accounts And Other Receivables 71 -453 +115.7%
Change in Inventory -410 98 -518.4%
Change in Prepaid & Other Assets -276 23 -1300.0%
Increase Decrease In Accounts Payable And Accrued Liabilities -185 625 -129.6%
Increase Decreasein Pension Benefit Obligation 23 -70 +132.9%
Inventory Recall Expense 98 38 +157.9%
Increase Decrease In Other Operating Capital Net 186 -445 +141.8%
Net Cash Provided By Used In Operating Activities Continuing Operations 3,430 3,844 -10.8%
Deferred Income Taxes -474 -211 -124.6%
Investing Activities
Capital Expenditures -760 -725 -4.8%
Payments For Proceeds From Investments 422 -421 +200.2%
Other Investing Activities -480 -444 -8.1%
Net Cash from Investing -818 -5,514 +85.2%
Financing Activities
Proceeds From Repayments Of Commercial Paper 455 400 +13.8%
Repayments Of Long Term Debt -1,789 -1,142 -56.7%
Share Repurchases -1,000 -500 -100.0%
Payments Of Dividends Common Stock -1,196 -1,100 -8.7%
Proceeds From Payments For Other Financing Activities -87 -89 +2.2%
Net Cash from Financing -3,617 2,087 -273.3%
Supplemental
Income Taxes Paid 599 653 -8.3%
Interest Paid 628 473 +32.8%
Other Cash Flow
Net Change in Cash -1,005 375 -368.0%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 851 1,856 -54.1%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key